Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy showed eplontersen met its co-primary endpoints... | March 27, 2023

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,United States ,American ,Eugene Schneider ,Sami Khella ,Penn Presbyterian Medical Center ,Astrazeneca ,Drug Administration ,Ionis Pharmaceuticals ,Columbia University Irving Medical Center ,Clinical Development ,University Of Pennsylvania School Medicine ,American Academy Of Neurology Annual Meeting ,Department Of Neurology ,Neuropathy Impairment Score ,Norfolk Quality ,Life Questionnaire Diabetic Neuropathy ,Clinical Neurology ,Pennsylvania School ,Executive Vice President ,Chief Clinical Development Officer ,American Academy ,Neurology Annual Meeting ,New Drug Application ,Orphan Drug Designation ,Emerging Science ,Rare Diseases ,Open Label Phase ,Neurol Ther ,University Irving Medical Center ,Drug Reduces Death ,Underdiagnosed Form ,Heart Failure ,Annual Report ,Global Phase ,Antisense Oligonucleotide ,Astrazeneca Plc Stock Exchange ,News ,Information ,Press Release ,Positive ,Results ,Rom ,The ,Hase ,Wii ,Trial ,N ,Patients ,Ith ,Hereditary ,Amyloid ,Polyneuropathy ,Howed ,Eplontersen ,Pet ,Ts Azn Gb0009895292 ,